BioSpring GmbH

BioSpring GmbH, also known as "THE NUCLEIC ACID COMPANY," is a pioneer in nucleic acid science and technology. The company, founded in 1997, has established itself as a leader in the biotechnology, healthcare, and manufacturing industries, offering high-quality cGMP manufacturing and analytics for clinical (Phase I-III) programs and commercial supply, as well as preclinical and diagnostic manufacturing. With a workforce of over 650 employees, BioSpring is committed to providing expert support throughout all phases of the drug development lifecycle, including regulatory filings.

Based in Frankfurt, Germany, BioSpring operates internationally, with a subsidiary in the United States and a local presence in Japan. The company's global reach, guided by more than 27 years of experience, reflects its passion for innovation and collaboration. BioSpring's mission is to partner with clients to maximize the potential of their technology, with the ultimate goal of advancing nucleic acid-based therapies to address debilitating diseases and contribute to a healthier world.

While specific investment details are not currently available, BioSpring's significant expertise and global presence position it as an intriguing prospect for potential investors and venture capital firms seeking to engage with a leading player in the nucleic acid field.

For more information, visit BioSpring's website and privacy notice at https://www.biospring.de/datenschutz-socialmedia/.